Announcement • Dec 20

Neurogene Inc. (NasdaqCM:NGNE) completed the acquisition of Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders for approximately $120 million in a reverse merger transaction.

Neurogene Inc. entered into a term sheet to acquire Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders in a reverse merger transaction on June 2, 2023. Neurogene Inc. entered into a definitive merger agreement to acquire Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $180 million in a reverse merger transaction on July 17, 2023. Subject to the terms of the merger agreement, each outstanding share of Neurogene capital stock will be converted solely into the right to receive a number of shares of Neoleukin common stock, equal to the exchange ratio, estimated to be approximately 1.7374 shares of Neoleukin common stock for each share of Neurogene’s common stock. Post merger Neoleukin stockholders are expected to own approximately 16% of the combined company and pre-merger Neurogene stockholders (including those purchasing Neurogene shares in the concurrent private financing) are expected to own approximately 84% of the combined company. Upon completion of the merger the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”. Under specified circumstances, Neoleukin may be required to pay Neurogene a termination fee of $3.04 million and Neurogene may be required to pay Neoleukin a termination fee of $12 million. The combined company will be led by Rachel McMinn, Founder and Chief Executive Officer of Neurogene, and other members of the Neurogene management team. The combined company’s Board of Directors will be comprised of five board members selected by Neurogene and two members selected by Neoleukin.The transaction is subject to approval by Neurogene and Neoleukin stockholders, the effectiveness of a registration statement, Nasdaq’s approval of the listing of the shares of Neoleukin common stock to be issued in connection with the merger, Neurogene’s receipt (or receipt simultaneous with the Closing of the merger) of cash proceeds from its private placement of not less than $75 million, Neoleukin net cash, as finally determined in accordance with the Merger Agreement, equaling an amount not less than $60 million and the satisfaction of customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both Neurogene and Neoleukin. Neoleukin’s board of directors unanimously recommends that Neoleukin stockholders vote for the merger. The merger is expected to close in the fourth quarter of 2023. TD Cowen is serving as exclusive financial advisor to Neurogene. TD Cowen and Stifel are serving as placement agents on Neurogene’s planned concurrent private financing. Ryan A. Murr and Branden C. Berns of Gibson Dunn & Crutcher LLP are serving as legal counsel and legal due diligence provider to Neurogene and Cooley LLP is serving as legal counsel to the placement agents. Leerink Partners LLC acted as the exclusive financial advisor and fairness opinion provider to Neoleukin Board. David K. Michaels and Jeremy R. Delman of Fenwick & West LLP are serving as legal counsel and legal due diligence provider to Neoleukin. Equiniti Trust Company, LLC acted as transfer agent for Neoleukin and American Stock Transfer & Trust Company, LLC acted as transfer agent for Neurogene. Morrow Sodali LLC acted as proxy solicitor to Neoleukin for a fee of $20,000, plus reimbursement of out-of-pocket expenses. In connection with Leerink Partners’ services as financial advisor to Neoleukin, Neoleukin has agreed to pay Leerink Partners an aggregate fee of $2.5 million, $500,000 of which became payable upon the rendering of its opinion and the remainder of which is payable contingent upon consummation of the merger.Neurogene Inc. (NasdaqCM:NGNE) completed the acquisition of Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders for approximately $120 million in a reverse merger transaction on December 18, 2023. As a result of and upon the effective time of the Merger (as defined herein), among other things, (a) each then-issued and outstanding share of Class A Common Stock, par value $0.0001 per share, of Neurogene (“Neurogene Class A Common Stock ”) converted automatically into 0.0756 shares of common stock, par value $0.000001 per share, of Neoleukin (the “Company Common Stock” and prior to the effective time of the Merger, the “Neoleukin Common Stock”), (b) each then-issued and outstanding share of Class B Common Stock, par value $0.0001 per share, of Neurogene (“Neurogene Class B Common Stock” and, together with Neurogene Class A Common Stock, “Neurogene Common Stock”), converted automatically into 0.0756 shares of Company Common Stock, (c) each then-issued and outstanding share of Series A-1 Preferred Stock, par value $0.0001 per share, of Neurogene (“ Neurogene Series A-1 Preferred Stock ”) converted automatically into 0.0756 shares of Company Common Stock, (d) each then-issued and outstanding share of Series A-2 Preferred Stock, par value $0.0001 per share, of Neurogene (“Neurogene Series A-2 Preferred Stock”) converted automatically into 0.0756 shares of Company Common Stock, (e) each then-issued and outstanding share of Series B Preferred Stock, par value $0.0001 per share (“Neurogene Series B Preferred Stock” and together with the Neurogene Common Stock, the Neurogene Series A-1 Preferred Stock and the Neurogene Series A-2 Preferred Stock, the “Neurogene Capital Stock”) converted automatically into 0.0756 shares of Company Common Stock, and (f) each then-issued and outstanding pre-funded warrant of Neurogene, each representing a right to acquire one share of Neurogene Common Stock for $1.559999 per pre-funded warrant (each, a “Neurogene Pre-Funded Warrant”), converted automatically, on a one-for-one basis, into a pre-funded warrant of the Company (each, a “ Company Pre-Funded Warrant”) that represents a right to acquire 0.0756 shares of Company Common Stock at an exercise price of $0.000001 per share. In connection with the completion of the Merger, Neoleukin changed its name from “Neoleukin Therapeutics, Inc.” to “Neurogene Inc.” (the “Company Name Change”). As of December 19, 2023, Neurogene shares are expected to begin trading on the NASDAQ Global Market under the ticker “NGNE” beginning today at the market open. The Board has determined that Robert Baffi, Cory Freedland, Sarah Noonberg, Rohan Palekar and Robert Keith Woods (“ Keith Woods ”), each of whom is a current member of the Board, qualify as “independent directors” as defined by the Nasdaq Listing Rules. The Neoleukin board of directors previously determined that former directors Martin Babler, M. Cantey Boyd, Erin Lavelle, Todd Simpson and Rusty Williams were “independent” under the Nasdaq Listing Rules. Immediately after the effective time the Merger on December 18, 2023, the Board appointed Rachel McMinn as the Company’s Chief Executive Officer and Christine Mikail as the Company’s President and Chief Financial Officer, each to serve at the discretion of the Board. Immediately after the effective time the Merger on December 18, 2023, the Board appointed the following four individuals to the Board: Rachel McMinn, Robert Baffi, Cory Freedland and Keith Woods. Rachel McMinn was also appointed as Chair of the Board. Concurrent with the closing of the merger, Neurogene closed an oversubscribed $95 million private financing, led by new and existing healthcare-dedicated specialist and mutual fund institutional investors, including participation from Great Point Partners, EcoR1 Capital, Redmile Group, Samsara BioCapital, Janus Henderson Investors, funds and accounts managed by Blackrock, Casdin Capital, Avidity Partners, Arrowmark Partners, Cormorant Asset Management, Alexandria Venture Investments, and a healthcare investment fund. Neurogene’s cash, cash equivalents, and investments of approximately $200 million, before payment of final transaction-related expenses, are expected to fund operations and multiple potentially value-creating milestones into the second half of 2026. Neoleukin convened and adjourned the Special Meeting on December 13, 2023. At the Special Meeting, Neoleukin’s stockholders approved, among other matters, amendments to the amended and restated certificate of incorporation of Neoleukin to (i) increase the number of authorized shares of Company Common Stock from 20,000,000 shares (after giving effect to the 1-for-5 reverse stock split that was effected on September 25, 2023) to 500,000,000 (the “Authorized Share Increase”) and (ii) effect the Reverse Stock Split. Following the Special Meeting, the Neoleukin board of directors approved the Reverse Stock Split at a ratio of 1:4.

CEO salary percentage	19.28%
CEO tenure	8.6yrs
CEO ownership	6.5%
Management average tenure	2.6yrs
Board average tenure	2.7yrs

Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	-US$99m
Dec 31 2025	US$3m	US$619k	-US$90m
Sep 30 2025	n/a	n/a	-US$85m
Jun 30 2025	n/a	n/a	-US$84m
Mar 31 2025	n/a	n/a	-US$81m
Dec 31 2024	US$3m	US$595k	-US$75m
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	US$2m
Mar 31 2024	n/a	n/a	US$9m
Dec 31 2023	US$1m	US$468k	US$14m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$657k	US$448k	-US$55m

Name	Position	Tenure	Compensation	Ownership
Rachel McMinn	Founder	8.6yrs	US$3.21m	6.54% € 40.3m
Christine Cvijic	President	2.7yrs	US$2.75m	0.19% € 1.2m
Julie Jordan	Chief Medical Officer	2.6yrs	US$1.47m	0.018% € 111.5k
Stuart Cobb	Chief Scientific Officer	2.7yrs	US$784.32k	0% € 0
Lina Li	Executive Director of Investor Relations	no data	no data	no data
Donna Cochener-Metcalfe	Senior VP	2.5yrs	no data	0.0010% € 6.2k
Andrew Mulberg	Senior VP of Regulatory Affairs	no data	no data	no data
Ricardo Jimenez	Senior Vice President of Technical Operations	no data	no data	no data
Arvind Sreedharan	Senior Vice President of Business Operations	no data	no data	no data
Christina Shafer	Chief Commercial Officer	less than a year	no data	no data

Name	Position	Tenure	Compensation	Ownership
Rachel McMinn	Founder	2.7yrs	US$3.21m	6.54% € 40.3m
Christine Cvijic	President	less than a year	US$2.75m	0.19% € 1.2m
Robert Baffi	Independent Director	2.7yrs	US$240.48k	0.13% € 809.7k
Rohan Palekar	Independent Director	4.4yrs	US$244.48k	0.098% € 604.3k
Sarah Noonberg	Independent Director	7yrs	US$230.48k	0.10% € 638.4k
Cory Freedland	Lead Independent Director	2.7yrs	US$239.48k	0.073% € 449.7k
Robert Woods	Independent Director	2.7yrs	US$237.48k	0.073% € 449.7k

Data	Last Updated (UTC time)
Company Analysis	2026/08/10 20:25
End of Day Share Price	2026/08/10 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Whitney Ijem	Canaccord Genuity
Gum-Ming Lowe	Craig-Hallum Capital Group LLC
Debjit Chattopadhyay	Guggenheim Securities, LLC

Neurogene Management

Management criteria checks 2/4

Key information

Recent management updates

High number of new directors

Neurogene Inc. Announces Executive and Board Appointments

Neurogene Inc., Annual General Meeting, Jun 03, 2026

Neurogene Inc., Annual General Meeting, Jun 12, 2025

High number of new and inexperienced directors

Recent updates

New major risk - Shareholder dilution

Neurogene Inc. has completed a Follow-on Equity Offering in the amount of $124.999979 million.

Neurogene Inc. has filed a Follow-on Equity Offering.

Neurogene Reports Positive Long-Term Clinical Data From Phase 1/2 Trial Of NGN-401 Gene Therapy For Rett Syndrome

Neurogene Completes Dosing in Embolden Registrational Trial of Ngn-401 for Rett Syndrome

Neurogene Inc Highlights Data Supporting Therapeutic Rationale For ICV Delivery Method In CNS-Targeted Gene Therapy

High number of new directors

Neurogene Inc. Announces Executive and Board Appointments

Neurogene Inc., Annual General Meeting, Jun 03, 2026

Neurogene Inc. Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome

Neurogene Inc. Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome Multidomain

Neurogene Inc. Announces First Participant Dosed in Embolden™? Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025

Neurogene Inc. Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Inc.(NasdaqGM:NGNE) dropped from Russell 3000 Growth Index

Neurogene Inc. Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

Neurogene Inc., Annual General Meeting, Jun 12, 2025

Neurogene Inc. Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate Ngn-401 with Exact™? Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Neurogene Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Neurogene Inc. (NasdaqCM:NGNE) completed the acquisition of Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders for approximately $120 million in a reverse merger transaction.

CEO Compensation Analysis

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources